Skip to main content
Premium Trial:

Request an Annual Quote

Lumera Extends Deal to Develop Protein-Expression Array With Medical University of South Carolina

NEW YORK (GenomeWeb News) — Nanotechnology company Lumera yesterday said it has extended a collaboration with the Medical University of South Carolina to develop a mitochondrial protein-expression array.
The agreement grants Lumera the rights to commercialize all jointly developed intellectual property, the company said.
Lumera said the array will “measure the levels and modifications of patient mitochondrial proteins.” Changes in these proteins may be used as markers for “certain pathologies,” the company added.
The company said the assay will “have significant time and cost advantages over existing technologies.”
Lumera makes a Proteomic Processor instrument and NanoCapture microarray slides used to measure thousands of proteins simultaneously.
The collaboration will continue to develop the work of MUSC lead investigator Craig Beeson, the company said. “[W]hile academically interesting, this project has implications across pharma that are significant,” Timothy Londergan, Lumera’s bioscience business unit director said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.